| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Halobetasol Propionate (BMY30056, CGP14458; BMY 30056, CGP 14458; BMY-30056; CGP-14458; Ulobetasol propionate) is a potent and synthetic corticosteroid with anti-inflammatory activity. It is used as a dermatologic agent for the treatment of psoriasis.
| ln Vitro |
|
||
|---|---|---|---|
| ln Vivo |
|
||
| Animal Protocol |
|
||
| References |
Indian J Dermatol Venereol Leprol.2009 Mar-Apr;75(2):186-7;Am J Clin Dermatol.2005;6(5):311-6.
|
| Molecular Formula |
C25H31CLF2O5
|
|
|---|---|---|
| Molecular Weight |
484.96
|
|
| CAS # |
66852-54-8
|
|
| Related CAS # |
Halobetasol propionate-d5
|
|
| SMILES |
C[C@@]12[C@](C(CCl)=O)(OC(CC)=O)[C@@H](C)C[C@@]1([H])[C@]3([H])C[ C@H](F)C4=CC(C=C[C@]4(C)[C@@]3(F)[C@@H](O)C2)=O
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.16 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.16 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0620 mL | 10.3101 mL | 20.6203 mL | |
| 5 mM | 0.4124 mL | 2.0620 mL | 4.1241 mL | |
| 10 mM | 0.2062 mL | 1.0310 mL | 2.0620 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT03298581 | Withdrawn | Drug: Halobetasol Propionate | Plaque Psoriasis | Sun Pharmaceutical Industries Limited | January 1, 2017 | Phase 2 |
| NCT03212963 | Terminated Has Results | Drug: Halobetasol Topical Lotion | Plaque Psoriasis | Sun Pharmaceutical Industries Limited | March 21, 2017 | Phase 4 |
| NCT04720105 | Completed Has Results | Drug: Duobrii® | Palmoplantar Psoriasis Plaque Psoriasis |
Icahn School of Medicine at Mount Sinai |
November 19, 2020 | Phase 4 |
| NCT00715975 | Completed | Drug: halobetasol Drug: clobetasol |
Psoriasis | Azidus Brasil | July 2008 | Phase 2 Phase 3 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA